科研之友
微信
新浪微博
Facebook
分享链接
摘要
Sipuleucel-T has been shown to prolong overall survival, without commonly affecting prostate-specific antigen (PSA) or inducing objective disease regression; however, objective responses do occur. The need to continue androgen deprivation after complete response to sipuleucel-T is uncertain. Withdrawal of hormonal therapies has been associated with PSA and objective responses in men with prostate cancer; the optimal sequence for introduction and withdrawal of androgen-targeted agents and sipuleucel-T should be explored.
- 出版日期2014-4
